Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 09/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CALT vs. PTCT, ACAD, MENS, PCVX, KRYS, ACLX, ADMA, MLTX, MTSR, and MIRMShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), Jyong Biotech (MENS), Vaxcyte (PCVX), Krystal Biotech (KRYS), Arcellx (ACLX), ADMA Biologics (ADMA), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Its Competitors PTC Therapeutics ACADIA Pharmaceuticals Jyong Biotech Vaxcyte Krystal Biotech Arcellx ADMA Biologics MoonLake Immunotherapeutics Metsera Mirum Pharmaceuticals PTC Therapeutics (NASDAQ:PTCT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings. Which has stronger valuation and earnings, PTCT or CALT? Calliditas Therapeutics AB (publ) has higher revenue and earnings than PTC Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M6.00-$363.30M$6.978.75Calliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62 Do analysts recommend PTCT or CALT? PTC Therapeutics currently has a consensus target price of $69.00, indicating a potential upside of 13.18%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe PTC Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to PTCT or CALT? In the previous week, PTC Therapeutics had 16 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 17 mentions for PTC Therapeutics and 1 mentions for Calliditas Therapeutics AB (publ). PTC Therapeutics' average media sentiment score of 0.92 beat Calliditas Therapeutics AB (publ)'s score of -0.71 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Calliditas Therapeutics AB (publ) 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Is PTCT or CALT more profitable? PTC Therapeutics has a net margin of 35.65% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. PTC Therapeutics' return on equity of -106.31% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics35.65% -106.31% 30.61% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Do insiders and institutionals believe in PTCT or CALT? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, PTCT or CALT? PTC Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. SummaryPTC Therapeutics beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$861.40M$5.80B$10.16BDividend YieldN/A4.84%5.69%4.61%P/E Ratio-21.621.1674.7325.99Price / Sales0.7426.72470.3491.76Price / CashN/A19.5637.0859.91Price / Book37.746.7712.256.31Net Income-$43.96M-$4.20M$3.28B$270.66M7 Day PerformanceN/A7.88%1.39%3.52%1 Month PerformanceN/A11.04%7.70%6.79%1 Year Performance0.50%25.68%64.01%28.29% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoveragePTCTPTC Therapeutics3.6468 of 5 stars$57.16+0.4%$69.00+20.7%+88.9%$4.56B$806.78M8.241,410Insider TradeACADACADIA Pharmaceuticals4.3958 of 5 stars$25.65+1.0%$28.88+12.6%+51.7%$4.33B$957.80M19.31510Positive NewsAnalyst ForecastMENSJyong BiotechN/A$55.68+6.4%N/AN/A$4.23BN/A0.0031News CoverageGap DownHigh Trading VolumePCVXVaxcyte2.2918 of 5 stars$32.10-1.0%$130.00+305.0%-70.9%$4.17BN/A-7.81160Positive NewsAnalyst ForecastKRYSKrystal Biotech4.942 of 5 stars$143.14-1.4%$210.38+47.0%-27.4%$4.14B$290.52M29.06210Positive NewsACLXArcellx2.2443 of 5 stars$70.30-1.1%$114.31+62.6%+4.4%$3.91B$107.94M-20.6280Positive NewsADMAADMA Biologics3.7357 of 5 stars$16.22-1.2%$27.67+70.5%-4.7%$3.90B$474.17M19.02530Positive NewsMLTXMoonLake Immunotherapeutics2.5283 of 5 stars$59.15-3.2%$74.43+25.8%+17.0%$3.84BN/A-21.532Positive NewsMTSRMetseraN/A$36.46+3.9%$63.50+74.2%N/A$3.83BN/A0.0081Trending NewsAnalyst ForecastAnalyst RevisionMIRMMirum Pharmaceuticals3.2009 of 5 stars$75.07-3.0%$74.13-1.3%+81.3%$3.81B$336.89M-62.74140Analyst Forecast Related Companies and Tools Related Companies PTC Therapeutics Alternatives ACADIA Pharmaceuticals Alternatives Jyong Biotech Alternatives Vaxcyte Alternatives Krystal Biotech Alternatives Arcellx Alternatives ADMA Biologics Alternatives MoonLake Immunotherapeutics Alternatives Metsera Alternatives Mirum Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CALT Stock Alerts